# Study to Evaluate the Safety and Pharmacokinetics of CKD-331

> **NCT05335044** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 47 (actual)

## Conditions studied

- Hypertension and Dyslipidemia

## Interventions

- **DRUG:** CKD-331
- **DRUG:** EX5619

## Key facts

- **NCT ID:** NCT05335044
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-31
- **Primary completion:** 2022-06-23
- **Final completion:** 2022-07-12
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05335044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05335044, "Study to Evaluate the Safety and Pharmacokinetics of CKD-331". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05335044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*